Emergent BioSolutions faces questions from lawmakers in vaccine probe Emergent BioSolutions executives testify on Capitol Hill Replay Video UP NEXT The beleaguered biotech firm Emergent BioSolutions will face a congressional inquiry Wednesday, scrutinized for what investigators say are the "serious deficiencies" in their manufacturing that led to up to 15 million doses' worth of COVID-19 vaccine ingredients being compromised and disposed of because of cross-contamination. Top Emergent executives Fuad El-Hibri, the company's founder and executive chairman, and Robert Kramer, its chief exec...